Main menu


You are here

RSV

Vaccines have saved an estimated 154 million lives over past half-century--study

Researchers estimate vaccines have saved 154 million lives over past half-century

An international team of health and medical researchers including workers at the WHO, working with economists and modeling specialists, has found that the use of vaccines to prevent or treat disease has saved the lives of approximately 154 million people over the past half-century.

In their study, published in The Lancet, the group used mathematical and statistical modeling to develop estimates for lives saved due to vaccines and then added them together to find the total.

...

Country / Region Tags: 
Problem, Solution, SitRep, or ?: 

US respiratory virus activity falls to low levels --CDC

US indicators for flu, COVID, and respiratory syncytial virus (RSV) declined further last week, with no states reporting moderate, high, or very high activity, down from one the week before, the Centers for Disease Control and Prevention (CDC) said Friday in its weekly updates. ...

Country / Region Tags: 
Problem, Solution, SitRep, or ?: 

U.S. US respiratory virus cases continue to decline except in two states

Respiratory virus activity from flu, COVID-19, and respiratory syncytial virus (RSV) continues to decline across most of the country, with only two jurisdictions—North Dakota and Wyoming—reporting high activity, the Centers for Disease Control and Prevention (CDC) said in updates today. ...

Hospitalizations continue to decline, but overall deaths were up slightly.

 

 

Country / Region Tags: 
Problem, Solution, SitRep, or ?: 

US respiratory virus activity declines, with few hot spots except North Dakota --CDC

Activity from the three main respiratory viruses continues to decline in the United States, with one of the main flu markers—outpatient visits for flulike illness—now below the national baseline for the first time since October, the Centers for Disease Control and Prevention (CDC) said today in its latest updates for flu, COVID, and respiratory syncytial virus (RSV).

Country / Region Tags: 
Problem, Solution, SitRep, or ?: 

Pfizer’s RSV vaccine shows potential to protect high-risk adults ages 18-59

Pfizer’s RSV vaccine shows potential to protect high-risk adults ages 18-59, widening possible use

A vaccine from Pfizer showed the potential to protect adults ages 18 to 59 who are at increased risk of getting severely sick from respiratory syncytial virus in a late stage clinical trial, the company said Tuesday.

...

 

 

 

 

 

 

Country / Region Tags: 
Problem, Solution, SitRep, or ?: 

Pages

Subscribe to RSV
howdy folks